Back to results
US 2024/0246903 A1Published application
Indanone and tetraloneketo or hydroxyl oximes as cancel therapeutics
AssigneeBoard of Regents, The University of Texas System
InventorsStanton McHardy, Michael W. Tidwell, Andrew J. Brenner, Ratna K. Vadlamudi
Life of this patent
Estimating the term…
Abstract
Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ERβ selective and/or ERβ specific ligands.
Claims17
A compound of Formula I:
- wherein,
- R1 and R2 are independently hydrogen, alkyl, branched alkyl, substituted alkyl, aryl, substituted aryl, —CH2-Aryl, or —CH2-substituted aryl;
- X is selected from O, —OH, N—OH, Hz, —O—R4, bonded by a single bond or double bond, wherein R4 is selected from hydrogen, alkyl, branched alkyl, heteroalkyl, aryl, heteroaryl, —CH2-aryl, or —CH2-heteroaryl;
- and n is 1 or 2.
1 more element
The compound of claim 8 or claim 9, wherein the halogen flourine.
Dependencies are inferred from the claim text.